| Biomarker ID | 656 |
| PMID | 21592298 |
| Year | 2011 |
| Biomarker | minichromosome maintenance protein 7 (MCM7) |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Progression Vs No Progression |
| Odds Ratio/Hazard Ratio/Relative Risk | Univariate: RR: (2.4, 95% CI: 1.5–3.9) |
| Effect on Pathways | Pathways include:- DNA strand elongation, G2/M checkpoints, MicroRNA regulation of DNA damage response, CDK regulation of DNA replication, G1 to S cell cycle control |
| Experiment | Progression Free Survival Vs No Progression Free Survival |
| Type of Biomarker | Prognostic |
| Cohort | 247 patients with prostate cancer were undertaken for the study. GS distribution was as follows: GS < 7, n = 60 (24.3%); GS = 7, n = 79 (32.0%); and GS > 7, n = 108 (43.7%). |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.001 |
| Method Used | Immunohistochemistry |
| Clinical | No |
| Remarks | Did not reach statistical significance in multivariate models |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | MCM7 |